Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women (Genome Medicine, (2022), 14, 1, (64), 10.1186/s13073-022-01063-5)

0Citations
Citations of this article
N/AReaders
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], an error was identified in the Funding section. The section currently reads: This study was funded by the European Union’s Horizon 2020 European Research Council Programme, H2020 BRCA-ERC under Grant Agreement No. 742432 as well as the charity The Eve Appeal (https:// eveap peal. org. uk). Additional aspects of the study were supported by the Swedish Research Council Grant # 2017-00932, 2012-02961, Region Stockholm and Karolinska Institutet (ALF), Cancerfonden (Grant no. CAN 2016/696), and Radiumhem- mets Forskningsfonder (# 154143, 184033) as well as by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The work carried out by TEB was supported by MRC grant MR/P014070/1. It should read.

Cite

CITATION STYLE

APA

Bartlett, T. E., Evans, I., Jones, A., Barrett, J. E., Haran, S., Reisel, D., … Widschwendter, M. (2022, December 1). Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women (Genome Medicine, (2022), 14, 1, (64), 10.1186/s13073-022-01063-5). Genome Medicine. BioMed Central Ltd. https://doi.org/10.1186/s13073-022-01086-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free